Organon (OGN) and Shanghai Henlius Biotech said Monday the phase 3 trial of investigational Perjeta biosimilar HLX11 met its primary endpoint of total pathological complete response.
The study compared the efficacy of HLX11 with Perjeta, or pertuzumab, in locally advanced breast cancer, the companies said. Secondary endpoints are currently being analyzed.
Henlius agreed to license the global commercialization rights, except in China, for HLX11 and another biosimilar candidate to Organon in 2022, the companies said.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。